Medicenna Therapeutics Completes Enrollment in Global Phase 1/2 Study of MDNA11
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicenna Therapeutics Corp. announced the completion of enrollment in its global Phase 1/2 ABILITY-1 study of MDNA11. A total of 152 patients were enrolled across Canada, US, Australia, Europe, and South Korea.
From recorder.ca
Why it matters
The enrollment milestone is considered important for the advancement of MDNA11, an investigational long-acting IL-2 Superkine designed for cancer and autoimmune diseases. The company plans to present updated study results at SITC 2026 and host a key opinion leaders webinar.
From recorder.ca